143 related articles for article (PubMed ID: 1687293)
21. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
Colao A; Merola B; Sarnacchiaro F; Di Sarno A; Landi ML; Marzullo P; Cerbone G; Ferone D; Lombardi G
Horm Res; 1995; 44(5):222-8. PubMed ID: 8582715
[TBL] [Abstract][Full Text] [Related]
22. Dopamine agonists and pituitary tumor shrinkage.
Bevan JS; Webster J; Burke CW; Scanlon MF
Endocr Rev; 1992 May; 13(2):220-40. PubMed ID: 1352243
[TBL] [Abstract][Full Text] [Related]
23. Treatment of extensively invasive (giant) prolactinomas with bromocriptine.
Grebe SK; Delahunt JW; Feek CM
N Z Med J; 1992 Apr; 105(931):129-31. PubMed ID: 1560924
[TBL] [Abstract][Full Text] [Related]
24. [Treatment of macroprolactinomas with quinagolide (Norprolac)].
Tabarin A; Catargi B
Ann Endocrinol (Paris); 1997; 58(2):87-94. PubMed ID: 9239226
[TBL] [Abstract][Full Text] [Related]
25. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
Pereira JL; García-Luna PP; Leal-Cerro A; Cortés A; Trujillo F; Villamil F; Vaquero F; Revuelta M; Astorga R
Med Clin (Barc); 1994 Jun; 103(2):59-64. PubMed ID: 8051973
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
Rohmer V; Freneau E; Morange I; Simonetta C
Ann Endocrinol (Paris); 2000 Nov; 61(5):411-7. PubMed ID: 11084391
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas.
Bhansali A; Walia R; Dutta P; Khandelwal N; Sialy R; Bhadada S
Indian J Med Res; 2010 Apr; 131():530-5. PubMed ID: 20424304
[TBL] [Abstract][Full Text] [Related]
28. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
[TBL] [Abstract][Full Text] [Related]
29. Pre- and post-operative hypothalamic-pituitary-thyroidal axis function in patients with prolactinoma, growth hormone tumour and ACTH tumour.
Lu C; Lin XT; Yang DT; Liu YC; He WT; Zhong XL
Chin Med J (Engl); 1989 Apr; 102(4):306-12. PubMed ID: 2551602
[TBL] [Abstract][Full Text] [Related]
30. Long term treatment with CV 205-502 in patients with prolactin-secreting pituitary macroadenomas.
Serri O; Beauregard H; Lesage J; Pedneault L; Comtois R; Jilwan N; Somma M; Vachon L; Brownell J
J Clin Endocrinol Metab; 1990 Sep; 71(3):682-7. PubMed ID: 2394774
[TBL] [Abstract][Full Text] [Related]
31. Giant prolactinomas in men: efficacy of cabergoline treatment.
Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
[TBL] [Abstract][Full Text] [Related]
32. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy.
Delgrange E; Duprez T; Maiter D
Clin Endocrinol (Oxf); 2006 Apr; 64(4):456-62. PubMed ID: 16584520
[TBL] [Abstract][Full Text] [Related]
33. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502.
Vance ML; Lipper M; Klibanski A; Biller BM; Samaan NA; Molitch ME
Ann Intern Med; 1990 May; 112(9):668-73. PubMed ID: 1970714
[TBL] [Abstract][Full Text] [Related]
34. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size.
van 't Verlaat JW; Croughs RJ
Clin Endocrinol (Oxf); 1991 Mar; 34(3):175-8. PubMed ID: 2036725
[TBL] [Abstract][Full Text] [Related]
35. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
36. Effects of a new prolactin inhibitor, CV 205-502, in the treatment of human macroprolactinomas.
Khalfallah Y; Claustrat B; Grochowicki M; Flocard F; Horlait S; Serusclat P; Sassolas G
J Clin Endocrinol Metab; 1990 Aug; 71(2):354-9. PubMed ID: 1974262
[TBL] [Abstract][Full Text] [Related]
37. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
Morange I; Barlier A; Pellegrini I; Brue T; Enjalbert A; Jaquet P
Eur J Endocrinol; 1996 Oct; 135(4):413-20. PubMed ID: 8921822
[TBL] [Abstract][Full Text] [Related]
38. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
Brue T; Pellegrini I; Gunz G; Morange I; Dewailly D; Brownell J; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
[TBL] [Abstract][Full Text] [Related]
39. Quinagolide in the management of prolactinoma.
Schultz PN; Ginsberg L; McCutcheon IE; Samaan N; Leavens M; Gagel RF
Pituitary; 2000 Dec; 3(4):239-49. PubMed ID: 11788012
[TBL] [Abstract][Full Text] [Related]
40. Treatment of macroprolactinomas at Auckland Hospital 1975-91.
Wallace EA; Holdaway IM
N Z Med J; 1995 Feb; 108(994):50-2. PubMed ID: 7885646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
